Achilles Therapeutics announced the formation of a Scientific Advisory Board (SAB) with three world-renowned appointments: Dr. Elizabeth M. Jaffee, Dr. Scott Antonia and Dr. Christopher A. Klebanoff. The SAB will work closely with Achilles' senior management team and Founders to advance the Company's pipeline of solid tumor cancer therapies. Dr. Elizabeth M. Jaffee is an internationally recognized expert in cancer immunology and pancreatic cancer, and currently serves as the Deputy Director of the Sidney Kimmel Comprehensive Cancer Center, Deputy Director of the Institute of Clinical and Translational Research, and professor of oncology at Johns Hopkins School of Medicine. Dr. Scott Antonia serves as the chair of the thoracic oncology department at the H. Lee Moffitt Cancer Center and Research Institute and is professor of oncologic sciences at the University of South Florida College of Medicine. Dr. Christopher A. Klebanoff is a leading cellular immunologist and medical oncologist at Memorial Sloan Kettering. Prior to joining MSK, he was an assistant clinical investigator and an NIH-Howard Hughes Medical Institute Research Scholar at the US National Institutes of Health in Bethesda, MD.